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Abbreviations list 
 
AF = Atrial fibrillation  
ARIC = Atherosclerosis Risk In Communities Study 
AUC = area under curve 
CAD = coronary artery disease 
CHARGE-AF = Cohorts for Heart and Aging Research in Genomic Epidemiology-Atrial Fibrillation 
CI = confidence interval 
COPD = chronic obstructive pulmonary disease 
FHS = Framingham Heart Study 
HF = heart failure 
HR = hazard ratio 
ICD = International Classification of Disease 
IR = incidence rate 
IS = ischemic stroke 
NHIS = National Health Insurance Service 
PLA = People’s Liberation Army 
ROC = receiver operating characteristic 
SD = standard deviation 
SHD = structural heart disease 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
Abstract 
Background: The incidence of atrial fibrillation (AF) is increasing, conferring a major healthcare 
issue in Asia. No risk score for predicting incident AF has been specifically developed in Asian 
subjects. Our aim was to investigate risk factors for incident AF in Asian subjects and to combine 
them into a simple clinical risk score. 
Methods: Risk factors for incident AF were analyzed in 471,446 subjects from the Chinese Yunnan 
Insurance Database (internal derivation cohort), and then combined into a simple clinical risk score. 
External application of the new score was performed in 451,199 subjects from the Korean National 
Health Insurance Service (external cohort). 
Results: In the internal cohort, structural heart disease (SHD), heart failure (HF), age≥75 years, 
coronary artery disease (CAD), hyperthyroidism, chronic obstructive pulmonary disease (COPD) and 
hypertension were associated with incident AF. Given the low prevalence and the strong association 
of SHD with incident AF (hazard ratio: 26.07 [18.22-37.30], p<0.001), these patients should be 
independently considered as ‘high-risk’ for AF and were excluded from the analysis. The remaining 
predictors were combined into the new simple C2HEST score: C2: CAD / COPD (1 point each); H: 
Hypertension; E: Elderly (Age≥75, doubled); S: Systolic HF (doubled); T: Thyroid disease 
(hyperthyroidism). The C2HEST score showed good discrimination with AUC 0.75 [0.73-0.77] and 
had good calibration (p=0.774). The score was internally validated by bootstrap sampling procedure, 
giving an AUC of 0.75 [0.73-0.77]. External application gave an AUC of 0.65 [0.65-0.66]. The 
C2HEST score was superior to CHADS2 and CHA2DS2VASc scores in both cohorts in predicting 
incident AF. 
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Conclusions: We have developed and validated the C2HEST score as a simple clinical tool to assess 
the individual risk of developing AF in the Asian population without SHD.  
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Introduction 
Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and is associated with an 
increased risk of ischemic stroke (IS), heart failure (HF), coronary artery disease (CAD) and 
mortality1-3. The 2010 Global Burden of Disease Study demonstrated that the worldwide 
age-adjusted prevalence of AF is 596 per 100,000 men and 373 per 100,000 women4. The incidence 
of AF increases dramatically with the development of incident risk factors for AF, such as ageing, 
hypertension, HF, CAD and chronic obstructive pulmonary disease (COPD). Indeed, this arrhythmia 
confers a major healthcare burden in Asia. For example, Japan will have 1 million AF patients, and 
China will have 9 million AF patients by 20505,6.  
 
Considering that many patients with incident AF are asymptomatic, a considerable number of 
patients are only diagnosed with AF when presenting with the AF-related complications. Because of 
this under-diagnosis, the actual prevalence of AF could be considerably higher7,8. Hence, risk 
evaluation and early identification through screening would be important to allow the targeting of 
early prevention strategies and improve prognosis9,10. Therefore, effective and cost-effective 
strategies should focus on identifying patients who are at higher risk of incident AF.  
 
Several clinical risk scores have been developed to predict incident AF, including the Framingham 
Heart Study (FHS) score11, the Atherosclerosis Risk In Communities Study (ARIC) score12 and the 
Cohorts for Heart and Aging Research in Genomic Epidemiology-Atrial Fibrillation (CHARGE-AF) 
score13. These three scoring systems were all derived from large follow-up cohorts and have good 
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predictive ability for incident AF11-13. However, they require many instrumental and laboratory 
variables to be calculated, being generally too complicated for everyday clinical application. 
Moreover, many of the previous scores were derived in Western populations, and a predictive score 
for incident AF in an Asian population has been never been developed. This is relevant, given that 
risk factors for AF may be different between Western and Asian populations14,15. 
 
Our primary objective was to analyze risk factors for incident AF in a large cohort of Asian subjects, 
which were combined into a simple clinical risk stratification score, which would be easy and 
practical to apply in everyday practice. 
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Methods 
Derivation cohort 
Details of the derivation database, the Yunnan Medical Insurance Database, have been described 
previously16. In brief, this is a medical insurance database in Yunnan Province, China, including >10 
million individuals from January 1, 2001, through December 30, 201216. This medical insurance 
scheme covers urban residents in Yunnan Province, located in the far southwest of China, spanning 
approximately 394,000 km2 and with a population of 46.3 million (2011 population statistics), 
representing 3% of the total Chinese population. It was part of governmental medical insurance plan, 
ensuring all participants had a permanent and personal registration number, through which the 
information of medical history, drugs, and mortality data recorded could be collected. All medical 
information of participants was obtained from local 2A- and 3A-grade hospitals which guaranteed 
the reliability of records regarding any medical service. Random sampling was performed on the 
enrolled individuals biennially, based on the periods of 2001-2002, 2003-2004, 2005-2006, 
2007-2008, 2009-2010, 2011-2012. A total of 1,228,539 people was selected. After excluding people 
with incomplete data (n=2,611 cases), readmission (n=754,582) and prevalent AF at baseline (n=30), 
471,446 cases were entered in the final analysis16.  
 
This derivation study was approved by the medical ethics committee of Chinese PLA (People’s 
Liberation Army) General Hospital (Approval No. 13BJZ40). The definition of AF and other risk 
factors were according to the International Classification of Diseases (ICD), Ninth Revision/10th 
revision (Supplementary data). AF was defined based on an ECG or Holter recording. The inclusion 
criteria for an AF case were limited to inpatients, with AF diagnosis confirmed on admission and 
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discharge. The accuracy of AF diagnosis was validated previously using sensitivity analysis16. 
Patients with paroxysmal AF were also included in the incident analysis. Patients with rheumatic 
heart disease were those who suffered from rheumatic fever and concomitant valvular heart disease 
(ie. mitral stenosis). Patients with structural heart disease (SHD) included those patients with 
rheumatic heart disease and dilated cardiomyopathy. 
 
External application 
The external cohort study was based on the Korean National Health Insurance Service 
(NHIS)-Health Screening (HealS) cohort released in 2015, including subjects who participated in 
health screening programs provided by the NHIS in the Republic of Korea in 2002 and 2003. This 
external cohort consisted of 514,764 Koreans subjects aged 40 to 80 years, who comprised a 10% 
simple random sample of all health screening participants. A total of 55.3% of the participants lived 
in non-metropolitan areas, which covers some urban areas and all rural areas. The follow up started 
from 2002 through 2013, with a mean duration of 87.3±17.6 months. Detailed information and 
profile of the NHIS-HealS Cohort has been described in a previous report17. The baseline 
demography for this external cohort is summarized in online Supplementary Table S1. 
 
This study was approved by the Institutional Review Board of Yonsei University Health System, and 
the informed consents were waived. We excluded subjects by following criteria: (i) those diagnosed 
with AF before conducting the health check-ups (n=5,019), and (ii) those with valvular heart disease 
(n=935; with a diagnosis of mitral stenosis [ICD-10: I05.0, I05.2, and I34.2] or prosthetic heart 
valves [ICD-10: Z95.2–Z95.4], and insurance claims for valve replacement or valvuloplasty), and (iii) 
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those with cardiomyopathy (n=357) [ICD-10: I42.0-I42.2]. Finally, a population cohort of 451,199 
patients was included for this analysis. Patients were defined as having new-onset AF as follows: i) if 
there was a discharge diagnosis of AF for inpatients with no prior history of AF’; or ii) when an 
episode of AF was detected in an outpatient and confirmed by a specialist. This strategy of AF 
diagnosis has previously been validated in the NHIS database with a positive predictive value of 
94.1%18,19.  
 
Statistical analysis 
Continuous variables were reported as mean with standard deviation (SD) and categorical variables 
as observed number of patients (percentage). Annual incident rates were defined as the number of 
patients with incident AF divided by the number of person-years free of AF within a 1-year period.  
Multivariable Cox regression analysis was used for identifying independent risk factors for incident 
AF over 11 years of follow-up (mean 4.1 (SD = 3.5) years) in the derivation cohort. The new 
predictive score was obtained with a stepwise model selection procedure based on Akaike 
information criterion. The pool of variables was also confirmed by a removal approach with p-value 
threshold of 10%. Risk factors in the final model were tested for interaction, but no further 
improvement was possible by including interactions.  
The score was evaluated by means of time-dependent (at follow-up time 11 years) area under the 
curve (AUC) for the receiver operating characteristic (ROC) curve for predicting incident AF. 
Internal validation was obtained by means of 1000 bootstrap replicates and calibration was assessed 
by means of Gronnesby and Borgan test20. Performance of the external application was also 
evaluated as AUC in the whole Korean cohort.  
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The Kaplan-Meier curves were computed to present the survival rates free from AF during follow-up, 
after dividing patients into 3 groups (low, medium, and high risk) according to the new score. 
Given that the CHADS2, CHA2DS2VASc and HATCH scores have been previously reported to be 
associated with incident AF21-23, we also performed an exploratory analysis to investigate how the 
C2HEST score compares against these scores. 
All tests were two-tailed, a value of p<0.05 was considered as statistically significant. Analyses were 
performed using SPSS Statistics, version 23.0 (IBM) and R version 3.4.2.  
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Results 
Baseline characteristics of the derivation cohort are presented in Table 1. A total of 471,446 subjects 
entered the final analysis, in which 921 subjects developed AF during 11 years of follow-up (mean 
4.1, SD = 3.5 years) with an incidence of 0.5 per 1000 person-years. Compared with subjects without 
AF, the patients who developed AF were older (P<0.001), more frequently male (P<0.001), with 
higher rates of hypertension (p<0.001), CAD (p<0.001), COPD (p<0.001), previous IS, renal 
dysfunction, hyperthyroidism, HF (p<0.001) and SHD (p<0.001).  
 
Risk factors for incident AF and score development 
Univariate Cox regression analysis is shown in Table 2. On multivariable analysis, SHD, HF, age 
≥75 years, CAD, hyperthyroidism, COPD, and hypertension were independent risk factors for 
incident AF (Table 2). Given the low prevalence and very strong association of SHD with incident 
AF (Hazard Ratio: 26.07, 95% Confidence Interval [CI] 18.22-37.30, p<0.001), this subgroup of 
patients should be considered as being at (very) ‘high-risk’ for incident AF independently from other 
risk factors. Thus, this variable was excluded from the score. The HR of other risk factors 
significantly associated with incident AF did not change after removal of SHD from the 
multivariable model (not shown). 
 
We combined these independent risk factors into the new simple C2HEST score (Table 3): C2: CAD / 
COPD (1 point each); H: Hypertension (1 point); E: Elderly (Age ≥ 75, 2 points); S: Systolic HF (2 
points); T: Thyroid disease (1 point). Total score ranged from 0 to 8 points.  
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The score showed a good discrimination with AUC 0.750 (95%CI 0.730-0.771, Figure 1a) and a 
good calibration (p=0.774). The score was then internally validated by bootstrap sampling procedure, 
which gave an AUC of 0.749 (95% CI 0.729-0.769).  
When applied to the external cohort, the score showed moderate discrimination with AUC 0.654 
(95%CI 0.649-0.659, Figure 1b). 
 
Incident rates of AF and the C2HEST score 
Table 4 shows incidence rates (IR) and HRs at each point of the C2HEST score. We divided patients 
in the derivation cohort into three groups according to the C2HEST score: low (0-1 points, IR 
0.34%/year), medium (2-3 points, IR 2.60%/year) and high-risk (>3 points, IR 15.98%/year). 
Kaplan-Meier curves for risk categories (Figure 2) showed an increased risk of AF across the three 
groups (log-rank test p<0.001). 
 
Comparison of the C2HEST score with the CHADS2, CHA2DS2VASc and HATCH scores 
Based on time-dependent prognostic models, the C2HEST score had significantly better predictivity 
for incident AF, as compared to the CHADS2, CHA2DS2VASc and HATCH scores in the derivation 
cohort from China, as follows: 
• AUC CHADS2: 0.632, 95%CI: 0.604-0.660 (p<0.001 vs. C2HEST).  
• AUC CHA2DS2VASc: 0.687, 95%CI: 0.659-0.716 (p<0.001 vs. C2HEST). 
• AUC HATCH: 0.633, 95%CI: 0.598-0.667 (p<0.001 vs. C2HEST). 
In the external cohort from Korea, the C2HEST score also had significantly better predictivity for 
incident AF, as compared to the CHADS2, CHA2DS2VASc scores: 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
• AUC CHADS2: 0.637, 95%CI: 0.632-0.642 (p<0.001 vs. C2HEST).  
• AUC CHA2DS2VASc: 0.637, 95%CI: 0.632-0.642 (p<0.001 vs. C2HEST). 
while this difference was only marginally significant for HATCH score: 
• AUC HATCH: 0.646, 95%CI: 0.641-0.651 (p=0.059 vs. C2HEST). 
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Discussion 
 
To our knowledge, this is the largest cohort study from an Asian population, aimed at developing a 
simple risk assessment tool for incident AF. We investigated risk factors for incident AF and derived 
and validated the new C2HEST score as a user-friendly clinical score to assess individuals’ risk of 
developing incident AF.   
 
In the multivariable analysis, we found that independent risk factors for incident AF were SHD, HF, 
ageing (≥75 years), CAD, hyperthyroidism, COPD, and hypertension; all these risk factors were also 
demonstrated to increase the risk of incident AF in previous studies24-27. Indeed, SHD dramatically 
increases the risk of incident AF such that patients with SHD per se are very high risk of incident AF 
24
. Heart failure is also another significant and independent risk factor, with a 2 to 6-fold increase in 
the risk of incident AF25,26. The ARIC (Atherosclerosis Risk in Communities) study showed that 
stable CAD was an independent risk factor for incident AF (HR, 2.21; 95% CI, 1.71-2.84)12.   
 
As highlighted above, previous studies have proposed several predictive tools for incident AF, such 
as the FHS score, the ARIC score and the CHARGE-AF score11-13. All these scoring systems were 
derived from large cohorts and showed good predictive values (C statistics, 0.75-0.78). However, 
these scores require many instrumental and laboratory variables to be calculated. Recently, the Suita 
study in Japan has developed a risk score for incident AF with a good predictive power (C-statistics, 
0.75; 95% CI, 0.72-0.77)28. However, this score is complex (more than 16 points) and we could not 
compare the C2HEST score with the Suita study, as our dataset did not have reliable data on ‘cardiac 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
murmur’, which is could be regarded as subjective parameter based on physician auscultation.   
As an exploratory analysis, we do show that C2HEST score had significantly better predictivity for 
incident AF, as compared to the CHADS2, CHA2DS2VASc and HATCH scores in the derivation 
cohort. Similarly, in the external cohort, the C2HEST confirmed higher predictivity for incident AF 
than CHADS2, and CHA2DS2VASc scores, while it was only marginally significant compared to the 
HATCH score. These comparisons are with the caveat that these scores were not derived nor 
designed for the prediction of incident AF but they were elaborated for stroke risk stratification29,30 
or arrhythmia progression from paroxysmal to persistent AF31. 
 
In contrast, the C2HEST was specifically designed to predict incident AF, and we used established 
approach whereby a large Asian cohort was used to derive the score with internal validation using 
bootstrap and calibration methods– and we then externally applied it in an independent Asian 
population sample, for new onset AF. The risk factors included in the C2HEST score may be 
promptly deduced by a careful clinical evaluation of a patient with no need for any laboratory 
evaluation to calculate the individual risk of incident AF. 
 
Strengths and limitations 
This is the first study aimed at developing a simple, user-friendly clinical risk score, the C2HEST 
score, from a large (n=471,446) community-based Asian population with long follow-up. Also, we 
provided an external application using a nationwide cohort derived from another large Asian 
population dataset, the Korean NIHS dataset (n=451,199). The C2HEST score is easy to calculate 
and to apply in clinical practice and allows a good identification of patients at risk for incident AF.  
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Nevertheless, the present study has some limitations. There were some differences in the 
demographic characteristics and comorbidities between the Chinese and Korean cohorts, reflecting 
the different populations, healthcare system settings and the nature of the cohorts per se, that is, 
health insurance scheme data from one single China province (Yunnan) from local 2A and 3A-grade 
hospitals, and a nationwide sample of Korean subjects.   
 
The incidence of AF in the derivation cohort was also lower than that of Western populations which 
may result from under-diagnosis and ethnic differences. Asymptomatic AF may be under-represented, 
given that there was no opportunistic screening for AF performed in this study. Indeed, the lower 
incidence of AF in Asian populations compared with Western populations is in accordance with 
previous reports showing an incidence of AF of 0.50-1.37 per 1000 person-years in Asians vs. 
3.04-3.68 per 1000 person-years in Western populations, respectively32-35. The detection of 
asymptomatic AF is also problematic in large population studies considering the random pattern of AF 
onset.  Nevertheless, it would generally be impossible to screen half a million people for detecting 
asymptomatic AF, while such ‘AF screening’ work could be done only in small highly selected 
samples (and possibly underpowered), which would again diminish the power of a large 
population-targeted study. Therefore, in order to do such large population-based epidemiology study 
in developing countries, such as China and other Asian countries, we are using the most viable way – 
based on a simple ‘clinical score’ based approach. Another issue is that screening method selection 
could have major impact on results. 
 
Although we have excluded those patients with known AF at baseline according to available medical 
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records, there may have some patients with unknown AF (or transient AF) for which we could not 
confirm thorough AF screening at the patient level. However, this would not defeat the meaning of 
evaluating the subject’s risk of developing incident AF during follow-up. Indeed, patients with AF 
occurring transiently are associated with high incidence of another AF episode in the coming days36, 
and these patients usually have poor AF-related outcomes37,38. 
 
The derivation cohort subjects of the present study came from Yunnan Provence in the southwest of 
China and may not represent the whole of China and Asia. We could not compare the C2HEST score 
with other risk scores for incident AF, such as FHS and CHARGE-AF as some variables from these 
scores were not collected for this dataset. However, the use of such complicated scoring systems 
relies on easily accessible computing and information systems, which are not applicable in the 
relatively underdeveloped Asia area. The simplicity of C2HEST, which could be calculated by every 
clinical practitioner without relying on advanced information technology, may address the current 
unmet medical needs in Asia and help address the burden of AF in this part of the world. While we 
have performed external application in another very large Asian cohort from Korea, further 
validation of the C2HEST score is needed, especially in non-Asian cohorts (currently ongoing). 
Cultural health and environmental variations may be other factors which would have increased the 
complexity of any derived score (defeating the purpose of a simple clinical score for everyday 
practice), and are generally subordinated factors compared with clinical situations or disease 
conditions when making clinical decisions for the risk of incident AF.   
  
 
Conclusion 
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We have developed and validated the C2HEST score as a simple clinical score to assess the 
individual risk of developing AF in the Asian population. This novel score may help identify patients 
without SHD who are at risk of incident AF and may be targeted for prevention strategies. 
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Table 1. Baseline characteristics of 471,446 subjects included in the internal validation cohort. 
 
Characteristics 
Subjects without AF 
(n=470,525) 
Subjects with incident AF 
(n=921) 
P value 
Age, mean (SD), y 47 (16) 62 (12) <0.001 
Male sex, No. (%) 247,752 (52.7) 574 (62.3) <0.001 
Medical history, No. (%)    
Hypertension 45,444 (9.7) 236 (25.6) <0.001 
Diabetes 18,900 (4.0) 29 (3.1) 0.180 
CAD 14,813 (3.1) 187 (20.3) <0.001 
Hyperlipidemia 6,610 (1.4) 17 (1.9) 0.198 
Vascular disease 6,003 (1.3) 9 (1.0) 0.486 
COPD 1,687 (0.4) 25 (2.7) <0.001 
Previous IS 1,608 (0.3) 7 (0.8) 0.023 
Renal dysfunction 1,423 (0.3) 8 (0.9) 0.002 
Hyperthyroidism 971 (0.2) 5 (0.5) 0.025 
HF 700 (0.1) 43 (4.7) <0.001 
SHD 401 (0.1) 33 (3.6) <0.001 
Hypothyroidism 203 (0.0) 1 (0.1) 0.340 
CHA2DS2VASc score, 
median (IQR) 
1 [0-1] 2 [1-3] <0.001 
 
AF=atrial fibrillation; CAD=coronary artery disease; COPD=chronic obstructive pulmonary disease; 
HF=heart failure; IQR=interquartile range; IS=ischemic stroke; SD=standard deviation; 
SHD=structural heart disease; CHA2DS2VASc score=congestive heart failure, hypertension, age ≥75, 
diabetes, stroke, vascular disease, age 65-74, female. 
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Table 2 Hazard ratios of risk factors for incident atrial fibrillation. 
 
Risk factors 
Univariable analysis Multivariable analysis 
HR 95% CI P value HR 95% CI P value 
SHD 39.00 27.6-55.2 <0.001 26.1 18.2-37.3 <0.001 
HF 34.66 25.5-47.1 <0.001 7.95 5.76-11.0 <0.001 
Age ≥75 years 8.24 6.80-9.98 <0.001 5.83 4.80-7.09 <0.001 
CAD 7.01 5.97-8.23 <0.001 4.14 3.50-4.90 <0.001 
Hyperthyroidism 2.06 0.85-4.96 0.107 3.20 1.33-7.71 0.010 
COPD 6.81 4.57-10.1 <0.001 3.01 1.33-7.71 <0.001 
Hypertension 4.63 4.05-5.29 <0.001 3.24 2.82-3.73 <0.001 
Renal dysfunction 2.91 1.45-5.83 0.003    
Previous IS 2.13 1.01-4.49 0.046    
Hyperlipidemia 1.12 0.71-1.79 0.620    
Male 1.22 1.07-1.40 0.003    
Hypothyroidism 1.79 0.25-12.7 0.561    
Diabetes 0.61 0.42-0.89 0.009    
Vascular Disease 1.36 0.38-1.41 0.355    
HR=hazard ratio; CI=confidence interval; for other abbreviations see Table 1. 
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Table 3 The C2HEST score for incident atrial fibrillation 
 
Acronym Risk factor Points 
C2 CAD (1 point) / COPD (1 point) 1-2 
H Hypertension (1 point) 1 
E Elderly (Age ≥ 75, 2 points) 2 
S Systolic HF (2 points) 2 
T Thyroid disease (hyperthyroidism) (1 point) 1 
   
 Total points 0-8 
 AUC (c-index) 95% CI 
C2HEST score 0.749 0.729-0.769 
AUC=area under the curve; CI=confidence interval; for other abbreviations see Table 1. 
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Table 4 Annual incidence of atrial fibrillation by C2HEST score. 
 
Score Subjects (No.) Incident AF (No.) 
Incidence 
of AF * 
Hazard Ratio 95% CI 
0 310,117 246 0.18 1.00 - 
1 88,825 378 0.82 4.31 3.67-5.06 
2 19,270 148 2.31 12.8 10.4-15.6 
3 8,253 68 3.73 22.6 17.2-29.6 
4 1,373 68 16.1 97.0 74.1-127.0 
5 90 6 28.7 187.4 83.3-421.6 
≥6 45 7 59.8 332.0 156.6-704.0 
* Per 1000 person-year; AF= atrial fibrillation; CI=confidence interval. 
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Figure Legends 
 
Figure 1. Receiver operating characteristic (ROC) curves for the C2HEST score in predicting 
incident AF. Panel A. Internal cohort, Panel B. External cohort. 
 
Figure 2. Kaplan-Meier curves for risk categories according to the C2HEST score. Patients were 
divided into three groups low (0-1 points), medium (2-3 points) and high-risk (>3 points). 
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Figure 1a 
 
 
 
 
Figure 1b 
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Figure 2. 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
e-Appendix 1. 
 
AF was diagnosed upon an ECG or Holter recording (ICD-9 codes: 427.31 or ICD10 codes: 
I48). Rheumatic valvular disease (ICD-9 codes: 393-398; ICD-10 codes: I05, I06, I07, 
I09.9), dilated cardiomyopathy (ICD-9 codes: 425.4; ICD-10 codes: I42.0), HF (ICD-9 codes: 
428; ICD-10 codes: I42, I50, I110, I819), CAD (ICD-9 codes: 410-414; ICD-10 codes: I20-
I25), hyperthyroidism (ICD-9 codes: 242; ICD-10 codes: E05), hypothyroidism (ICD-9 codes: 
244; ICD-10 codes: E03), COPD (ICD-9 codes: 490-496; ICD-10 codes: J42, J44.0-9), 
hypertension (ICD-9 codes: 401-405; ICD-10 codes: I10-I15), renal dysfunction (ICD-9 
codes: 585, 586; ICD-10 codes: M1A.3), IS (ICD-9 codes: 436; ICD-10 codes: I63), 
hyperlipidemia (ICD-9 codes: 272.4; ICD-10 codes: E78.0-3, E78.5), myocardial infarction 
(ICD-9 codes: 410; ICD-10 codes: I21, I22), peripheral vascular disease (ICD-9 codes: 
440.2; ICD-10 codes: I65, I70-74), diabetes mellitus (ICD-9 codes: 249-250; ICD-10 codes: 
E10-E14). 
 
 
 
 
 
 
e-Table 1. Baseline characteristics of subjects in the validation cohort 
 
 
 
181293 
Characteristics 
Total subjects 
(n=451,199) 
Subjects 
without AF 
(n=439,056) 
Subjects with 
incident AF 
(n=12,143) 
P 
value 
Age, mean (SD), y 56.1 (9.3) 55.9 (9.3) 62.3 (9.9) <0.001 
Male sex, No. (%) 243,503 (54.0) 236220 (53.8) 7283 (60.0) <0.001 
Comorbidities 
Hypertension 143,168 (31.7) 136586 (31.1) 6582 (54.2) <0.001 
Diabetes mellitus 37,372 (8.3) 35752 (8.1) 1620 (13.3) <0.001 
Coronary artery 
disease 
9,946 (2.2) 
9029 (2.1) 917 (7.6) <0.001 
Hyperlipidemia 45,012 (10.0) 43234 (9.8) 1778 (14.6) <0.001 
Vascular disease 13,656 (3.0) 12837 (2.9) 819 (6.7) <0.001 
COPD 44,470 (9.9) 42120 (9.6) 2350 (19.4) <0.001 
Previous ischemic 
stroke 
14,980 (3.3) 14072 (3.2) 908 (7.5) <0.001 
Renal dysfunction 3,461 (0.8) 3267 (0.7) 194 (1.6) <0.001 
Systolic heart 
failure 
5,515 (1.2) 
5082 (1.2) 433 (3.6) 
<0.001 
Thyroid disease 2,477 (0.6) 2382 (0.5) 95 (0.8) <0.001 
CHA2DS2-VASc 
score, 
median (IQR) 
0 (0-1) 0 (0-1) 1 (0-2) <0.001 
